LILRB2 blockade facilitates macrophage repolarization and enhances T cell-mediated antitumor immunity
These findings support the potential of AZD2796 as an anti-cancer therapy, with the ability to synergize with T-cell-based therapeutics.
Authors
- Michael Kierny (ORCID: https://orcid.org/0000-0002-5409-0991)
- Alan M. Sandercock
- Andrew Kayserian
- Kamila Bienkowska (ORCID: https://orcid.org/0000-0003-4940-1895)
- Reena Varkey
- Stacy Pryts
- Lorraine Irving (ORCID: https://orcid.org/0000-0002-0816-5729)
- Matthew S. Glover (ORCID: https://orcid.org/0009-0003-9346-5121)
- Robert W. Wilkinson (ORCID: https://orcid.org/0000-0001-8180-2643)
- Shreya Ahuja (ORCID: https://orcid.org/0000-0001-8268-8600)
- Elisavet I. Chatzopoulou
- Rebecca Dudley
- D. Gareth Rees (ORCID: https://orcid.org/0000-0002-4268-6018)
- Saravanan Rajan (ORCID: https://orcid.org/0000-0002-5167-4932)
- Simon J. Dovedi (ORCID: https://orcid.org/0000-0003-0486-1206)
- Kathy Mulgrew (ORCID: https://orcid.org/0000-0001-9977-7597)
- Sonja Y. Hess (ORCID: https://orcid.org/0000-0002-5904-9816)
- Seraina Blümli (ORCID: https://orcid.org/0000-0001-6903-0740)
- Des C. Jones
- Fernanda I. Arnaldez (ORCID: https://orcid.org/0000-0003-1185-2498)
- Georgina Bowyer (ORCID: https://orcid.org/0000-0002-2058-4045)
- Mark Cobbold
- Saly Songvilay
- Marcin Wolny
Institutions
- AstraZeneca (United Kingdom) (GB)
- Immunocore (United Kingdom) (GB)
- AstraZeneca (Netherlands) (NL)
- AstraZeneca (Singapore) (SG)
- AstraZeneca (Japan) (JP)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1136/jitc-2024-010012
- Citations
- 8
- Primary Topic
- Immune Cell Function and Interaction
- Type
- article
- Field-Weighted Citation Impact
- 6.38
Funders
- AstraZeneca